IDXX Stock Analysis: IDEXX Laboratories | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 43.425m USD | 12M Return: -7.1% | US45168D1046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 293M
EPS Trend: 99.3%
Qual. Beats: 2
Rev. Trend: 98.5%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IDEXX Laboratories is a global veterinary and water diagnostics company headquartered in Westbrook, Maine, operating through three segments: Companion Animal Group (its core business), Water Quality Products, and Livestock, Poultry and Dairy. The company provides a broad suite of in-clinic diagnostic instruments and rapid assay test kits (such as chemistry, urinalysis, hematology, and SNAP tests), reference laboratory services, telemedicine and radiology consulting, and the VetConnect PLUS cloud platform that integrates patient data across practice workflows. Beyond animal health, IDEXX sells microbial water testing products like Colilert and Enterolert, and extends select offerings into livestock herd health and human diagnostics.
Founded in 1983 and public since 1991, IDEXX earns revenue primarily from recurring consumables-test kits and reagents used in its installed base of analyzers-paired with software subscriptions and lab services, which together produce the high-margin, recurring revenue profile characteristic of veterinary diagnostics. The company is widely viewed as the dominant scaled player in the companion animal diagnostics market, which benefits from long-running tailwinds in pet ownership and willingness to spend on advanced veterinary care.
- Companion Animal Group recurring revenue outpaces instrument placements
- Water testing demand rises on stricter global regulations
- Margins expand as installed base drives consumables pull-through
| Net Income: 1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.36 > 0.02 and ΔFCF/TA 13.08 > 1.0 |
| NWC/Revenue: 4.87% < 20% (prev 3.43%; Δ 1.44% < -1%) |
| CFO/TA 0.40 > 3% & CFO 1.37b > Net Income 1.14b |
| Net Debt (1.03b) to EBITDA (1.62b): 0.63 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.7m) vs 12m ago -0.39% < -2% |
| Gross Margin: 62.45% > 18% (prev 61.54%; Δ 0.91% > 0.5%) |
| Asset Turnover: 134.4% > 50% (prev 121.2%; Δ 13.23% > 0%) |
| Interest Coverage Ratio: 37.44 > 6 (EBIT TTM 1.46b / Interest Expense TTM 39.1m) |
| A: 0.06 (Total Current Assets 1.51b - Total Current Liabilities 1.29b) / Total Assets 3.44b |
| B: 2.04 (Retained Earnings 7.01b / Total Assets 3.44b) |
| C: 0.43 (EBIT TTM 1.46b / Avg Total Assets 3.39b) |
| D: 0.88 (Book Value of Equity 1.61b / Total Liabilities 1.83b) |
| Altman-Z'' = 10.89 = AAA |
| DSRI: 0.99 (Receivables 741.7m/663.5m, Revenue 4.55b/4.04b) |
| GMI: 0.99 (GM 61.54% / 62.45%) |
| AQI: 0.95 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 1.13 (Revenue 4.55b / 4.04b) |
| TATA: -0.07 (NI 1.14b - CFO 1.37b) / TA 3.44b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of November 03, 2026, the stock is trading at USD 671.64 with a total of 1,977,244 shares traded. Over the past week, the price has changed by +17.79%, over one month by +29.56%, over three months by +18.28% and over the past year by -7.10%.
Current recommended Stop Loss: 653.50 (which is 2.7% or 1.2 ATR below the current price).
IDEXX Laboratories has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy IDXX.
- StrongBuy: 5
- Buy: 4
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 694.4 | 3.4% |
P/E Trailing = 38.7358
P/E Forward = 33.3333
P/S = 9.5372
P/B = 26.9289
P/EG = 3.015
Revenue TTM = 4.55b USD
EBIT TTM = 1.46b USD
EBITDA TTM = 1.62b USD
Long Term Debt = 299.9m USD (from longTermDebt, last quarter)
Short Term Debt = 695.7m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter) + Leases 127.2m
Net Debt = 1.03b USD (calculated: Debt 1.22b - CCE 196.9m)
Enterprise Value = 44.5b USD (43.4b + Debt 1.22b - CCE 196.9m)
Interest Coverage Ratio = 37.44 (Ebit TTM 1.46b / Interest Expense TTM 39.1m)
EV/FCF = 35.54x (Enterprise Value 44.5b / FCF TTM 1.25b)
FCF Yield = 2.81% (FCF TTM 1.25b / Enterprise Value 44.5b)
FCF Margin = 27.47% (FCF TTM 1.25b / Revenue TTM 4.55b)
Net Margin = 25.03% (Net Income TTM 1.14b / Revenue TTM 4.55b)
Gross Margin = 62.45% ((Revenue TTM 4.55b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Gross Margin QoQ = 64.04% (prev 63.35%)
Tobins Q-Ratio = 12.91 (Enterprise Value 44.5b / Total Assets 3.44b)
Interest Expense / Debt = 3.20% (Interest Expense 39.1m / Debt 1.22b)
Taxrate = 19.99% (284.8m / 1.42b)
NOPAT = 1.17b (EBIT 1.46b * (1 - 19.99%))
Current Ratio = 1.17 (Total Current Assets 1.51b / Total Current Liabilities 1.29b)
Debt / Equity = 0.76 (Debt 1.22b / totalStockholderEquity, last quarter 1.61b)
Debt / EBITDA = 0.63 (Net Debt 1.03b / EBITDA 1.62b)
Debt / FCF = 0.82 (Net Debt 1.03b / FCF TTM 1.25b)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 33.65% (Net Income 1.14b / Total Assets 3.44b)
RoE = 71.96% (Net Income TTM 1.14b / Total Stockholder Equity 1.58b)
RoCE = 77.69% (EBIT 1.46b / Capital Employed (Equity 1.58b + L.T.Debt 299.9m))
RoIC = 44.13% (NOPAT 1.17b / Invested Capital 2.65b)
WACC = 7.09% (E(43.4b)/V(44.6b) * Re(7.22%) + D(1.22b)/V(44.6b) * Rd(3.20%) * (1-Tc(0.20)))
Discount Rate = 7.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.45 | Cagr: -1.76%
[DCF] Terminal Value 77.97% ; FCFF base≈1.06b ; Y1≈1.22b ; Y5≈1.79b
[DCF] Fair Price = 328.6 (EV 26.9b - Net Debt 1.03b = Equity 25.9b / Shares 78.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.31 | EPS CAGR: 15.16% | SUE: 2.97 | # QB: 2
Revenue Correlation: 98.52 | Revenue CAGR: 8.78% | SUE: 0.91 | # QB: 5
EPS current Year (2026-12-31): EPS=14.88 | Chg30d=+0.28% | Revisions=+79% | GrowthEPS=+13.7% | GrowthRev=+9.8%
EPS next Year (2027-12-31): EPS=16.73 | Chg30d=-0.04% | Revisions=+56% | GrowthEPS=+12.5% | GrowthRev=+8.9%
[Analyst] Revisions Ratio: +74% (up=22, down=2)